Physician profile
Timothy C Simplot
NPI 1275591273
$6,018.52
in general payments reported to CMS, 2019-2025
35 companies · $748 in 2025
The $748 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $351 · 2020: $422 · 2021: $1,210 · 2022: $1,955 · 2023: $808 · 2024: $525 · 2025: $748.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,082.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,081.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $1,088.68 | 2022 | |
| Aerin Medical INC. | $726.62 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $639.45 | 2019-2025 | Dupixent |
| Acclarent, INC | $606.40 | 2019-2023 | |
| Genzyme Corporation | $412.16 | 2019-2025 | |
| Optinose US, INC. | $377.69 | 2019-2025 | |
| Intersect Ent, INC. | $350.98 | 2019-2022 | |
| Karl Storz Endoscopy-America | $335.19 | 2019-2023 | N.A. |
| Stryker Corporation | $268.37 | 2019-2024 | Scopis Ent |
| Itamar Medical INC | $161.17 | 2022-2025 | Watchpatone |
| Takeda Pharmaceuticals U.S.A., INC. | $134.09 | 2019-2021 | |
| Smith+Nephew, INC. | $127.80 | 2019-2024 | Tula, Coblation |
| Phathom Pharmaceuticals, INC. | $87.72 | 2025 | Voquezna |
| Alk-Abello, INC | $74.71 | 2021-2022 | |
| Organogenesis INC. | $65.90 | 2023-2025 | Puraply, Puraply Wound Matrix |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $64.53 | 2021-2022 | |
| Medtronic, INC. | $60.04 | 2021-2024 | Propel |
| Amgen INC. | $57.03 | 2022-2025 | Tezspire |
| Integra Lifesciences Corporation | $49.58 | 2025 | Relieva Spinplus Nav, Trudi Probe, Inspira Air |
| Hologic Sales and Service, LLC | $45.72 | 2023-2025 | Coolseal Generator |
| Depuy Synthes Sales INC. | $28.74 | 2025 | Matrixmidface, Matrixmandible |
| Neurent Medical Limited | $28.34 | 2025 | Neuromark System, Neuromark Radiofrequency Console |
| Preceptis Medical, INC. | $22.70 | 2023 | Hummingbird Tympanostomy Tube System |
| Novartis Pharmaceuticals Corporation | $21.74 | 2025 | |
| Merz North America, INC. | $20.30 | 2019 | |
| Cochlear Americas | $19.65 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $18.71 | 2025 | Tezspire |
| Ethicon US, LLC | $18.51 | 2025 | Stratafix |
| Ars Pharmaceuticals Operations, INC. | $18.14 | 2025 | Neffy |
| Xoran Technologies LLC | $16.50 | 2021 | |
| Zimmer Biomet Holdings, INC. | $16.06 | 2019 | |
| Agiliti Surgical, INC. | $14.97 | 2019 | |
| Convatec INC. | $13.71 | 2024 | |
| Glaxosmithkline, LLC. | $13.40 | 2023 | Nucala |
| Jazz Pharmaceuticals INC. | $13.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Simplot listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.